

Catalog# BP-50196

Patritumab deruxtecan

Description:

Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab (HY-P99275) attached to a topoisomerase I inhibitor (a toxin component of Dxd) payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity. This product is for research use only. Patritumab deruxtecan has an approximate molecular weight of 158 kDa. The DAR is $n = \sim 3.4$. Mirvetuximab soravtansine has an anti-proliferative effect via growth arrest and augmented DNA damage. This product is for research use only.

Product Details	
CAS No.	2227102-46-5
Species Reactivity	Human
Type	Antibody-drug conjugate
ADC antibody	Patritumab (anti-HER3)
Target	Human HER3
ADC cytotoxin (drug)	Dxd
Purity	91.23%
DAR	~8
Molecular Weight	158kDa
Formulation	10 mg/mL in PBS buffer pH7.4
Purification	Size exclusive column
Storage conditions	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.